|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$104,000
|
N/A
|
National Institutes of Health
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-04S1
|
$1,393,520
|
$111,482
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-04
|
$400,000
|
$80,000
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-04
|
$22,547,116
|
$1,803,769
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
$1,425
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
$26,456
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Childhood Cancer Survivor Study
|
2U24CA055727-23
|
$3,616,741
|
$361,674
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
$67,654
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
$1,250
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SB
|
$59,999
|
$600
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Second generation MIBG analogs that cotarget DNA for high risk neuroblastoma
|
5R21CA187548-02
|
$163,669
|
$163,669
|
BARANOWSKA-KORTYLEWICZ, JANINA
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S2
|
$60,000
|
$600
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S3
|
$100,000
|
$1,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Fred & Pamela Buffett Cancer Center Support Grant
|
5P30CA036727-31
|
$2,107,000
|
$42,140
|
COWAN, KENNETH
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-41S1
|
$125,000
|
$7,500
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
MYC--Transcription and Apoptosis
|
5R01CA051497-26
|
$27,000
|
$13,500
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Myc - Transcription and Apoptosis
|
7R01CA051497-27
|
$350,375
|
$175,188
|
DANG, CHI
|
WISTAR INSTITUTE
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
1R01CA207983-01A1
|
$423,016
|
$296,111
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
5R01CA129377-10
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-22
|
$136,153
|
$68,077
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Structural Variation in Neuroblastoma
|
5R01CA204974-02
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery of New Differentiation Agents for Neuroblastoma Therapy
|
1R15CA213199-01A1
|
$461,575
|
$461,575
|
DU, LIQIN
|
TEXAS STATE UNIVERSITY
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-06
|
$363,425
|
$363,425
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523
|
2R42CA192656-02A1
|
$1,320,558
|
$1,320,558
|
DURDEN, DONALD
|
SIGNALRX PHARMACEUTICALS, INC.
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-26
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of Neuroblastoma
|
1R01CA215753-01A1
|
$391,698
|
$391,698
|
FABBRI, MULLER
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
ABT-199 based therapies to treat neuroblastoma
|
1R01CA215610-01
|
$371,856
|
$371,856
|
FABER, ANTHONY
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
2R01CA148688-06A1
|
$413,844
|
$413,844
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
5R01CA197336-02
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
VCU Massey Cancer Center Support Grant
|
2P30CA016059-36
|
$2,164,167
|
$108,208
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-36S1
|
$124,341
|
$6,217
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
VCU Massey Cancer Center Support Grant
|
3P30CA016059-36S2
|
$19,990
|
$1,000
|
GINDER, GORDON
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Dana-Farber/Harvard Cancer Center
|
2P30CA006516-52
|
$11,592,798
|
$115,928
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-52S1
|
$112,500
|
$1,125
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,583,320
|
$179,166
|
Glod, John
|
CCR (NCI)
|
|
Role of m6A mRNA methylation in Neuroblastoma
|
1R21CA219352-01
|
$246,472
|
$246,472
|
GREGORY, RICHARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-03
|
$366,000
|
$91,500
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Deciphering the Molecular Pathways Driving p53 Dependent Cell Death
|
5F32CA199716-04
|
$60,990
|
$30,495
|
GUARNIERI, ANNA
|
UNIVERSITY OF COLORADO DENVER
|
|
ENHANCING T CELL THERAPY OF CANCER
|
5P01CA094237-15
|
$1,932,287
|
$483,072
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Development of new antibody-based cancer therapies
|
ZIA BC 010891
|
$942,291
|
$942,291
|
Ho, Mitchell
|
CCR (NCI)
|
|
Altered mitochondria-ER signaling as a cause of chemotherapy resistance
|
5R21CA198430-02
|
$215,064
|
$215,064
|
HOGARTY, MICHAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Identification of novel cooperating partners of MYCN in neuroblastoma tumorigenesis
|
5K99CA197484-02
|
$160,773
|
$160,773
|
HUANG, MILLER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
|
ZIA BC 011334
|
$474,811
|
$47,481
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Developing Novel Therapies for Neuroblastoma and Rhabdomyosarcoma
|
ZIA BC 010806
|
$170,385
|
$85,192
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of Novel Mutations In Pediatric Cancers
|
ZIA BC 010998
|
$511,155
|
$204,462
|
Khan, Javed
|
CCR (NCI)
|
|
Bioinformatics: Systems Biology of Pediatric Cancers
|
ZIA BC 011002
|
$340,770
|
$340,770
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of Genes for Predicting Prognosis in Pediatric Cancers
|
ZIA SC 010366
|
$170,385
|
$85,192
|
Khan, Javed
|
CCR (NCI)
|
|
Bench to bedside: non-invasive treatment of tumors in children
|
1U01CA202947-01A1
|
$350,585
|
$87,646
|
KIM, PETER
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
5R01CA197964-03
|
$348,597
|
$174,299
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
Total relevant funding to Neuroblastoma for this search: $23,594,430
|